Prevalence of fatal adverse drug reactions in hospitalized patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 10, 2009, Pages 596-602

  Cabello, A J Pardo ^a   Contreras, L G González ^a   Gamero, M V Manzano ^a   Jiménez, F J Gómez ^a   Cañas, E Puche ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Adverse drug reactions; Epidemiology; Hospitalized patients; Mortality

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; DIGOXIN; ENOXAPARIN; KETOROLAC; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; DRUG; FIBRINOLYTIC AGENT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BONE MARROW SUPPRESSION; BRADYCARDIA; BRAIN HEMORRHAGE; CHILD; COMORBIDITY; DIGESTIVE SYSTEM ULCER; DRUG FATALITY; ENTEROCOLITIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PREVALENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; BLEEDING; CAUSE OF DEATH; CHEMICALLY INDUCED DISORDER; DRUG SURVEILLANCE PROGRAM; MIDDLE AGED; MORTALITY; REGISTER; RISK FACTOR; STATISTICS;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAUSE OF DEATH; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 70350712578     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47596     Document Type: Article

References (39)

1. Backstrom M, Mjorndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2004; 13: 483-487.
2. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006; 26: 601-608.
3. Carbonin P, Pahor M, Bernabei R, Sgadari A. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc. 1991 39: 1093-1099.
4. Carleton J, Chahal R, Dietz PA. Thromboembolic prophylaxis in orthopedic and general surgery. Curr Surg. 2005; 62: 161-168.
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987 40: 373-383.
6. Chyka PA. How many deaths occur annually from adverse drug reactions in the United States? Am J Med. 2000; 109: 122-130.
7. Domecq C, Naranjo CA, Ruiz I, Busto U. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol. 1980 18: 362-366.
8. Eaton L. Adverse reactions to drugs in crease. BMJ. 2002; 324: 8.
9. Ebbesen J, Buajordet I, Erikssen J, Brors O, Hilberg T, Svaar H, Sandvik L. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001; 161: 2317-2323.
10. Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993 27: 832-840.
11. Evans RS, Pestotnik SL, Classen DC, Horn SD, Bass SB, Burke JP. Preventing adverse drug events in hospitalized patients. Ann Pharmacother. 1994 28: 523-527.
12. Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996 14: 447-450.
13. Gore JM, Spencer FA, Goldberg RJ, Kennelly BM, Fox KA, Allegrone J, Eagle KA, Anderson FA Jr., Steg PG. Use of heparins in Non-ST-elevation acute coronary syndromes. Am J Med. 2007; 120: 63-71.
14. Hermosillo AJ, Spinler SA. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother. 2008; 42: 790-805.
15. Hoehns JD, Fouts MM, Kelly MW, Tu KB. Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother. 2001; 35: 862-866.
16. Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. Br Med J. 1969; 1: 531-536.
17. Juntti-Patinen L, Neuvonen PJ. Drug-related deaths in a university central hospital. Eur J Clin Pharmacol. 2002; 58: 479-482.
18. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J. In creased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358: 2678-2687.
19. Lazarou J, Pomeranz BH, Corey PN. Inci dence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200-1205.
20. Leone R, Sottosanti L, Luisa IM, Santuccio C, Conforti A, Sabatini V, Moretti U, Venegon M. Drug-related deaths: ananalysis of the Italian spontaneous reporting database. Drug Saf. 2008; 31: 703-713.
21. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007; 6: 981-993.
22. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
23. Petralia GA, Kakkar AK. Treatment of venous thrombo-embolism in cancer patients. Semin Thromb Hemost. 2007; 33: 707-711.
24. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329: 15-19.
25. Puche E, Luna JD. Adverse drug reactions: an update review of the problem in Spain. Rev Clin Esp. 2006; 206: 336-339.
26. Puche E, Luna JD. Adverse drug reactions in patients visiting a general hospital: a meta-analysis of results. An Med Interna. (Madrid) 2007; 24: 574-578.
27. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Davies DM, Ferner RE, de Glanville H (eds). Davies's text book of adverse drug reactions. Oxford: Oxford University Press, 1991: 18-45.
28. Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm. 2007; 64(17): 1840-1843.
29. Schulman S. Current strategies in prophylaxis and treatment of venous thromboembolism. Ann Med. 2008; 40: 352-359.
30. The National Board of Health and Welfare Centre for Epidemiology. Causes of Death 2001. Available at http://www.socialstyrelsen.se (last ac cessed: 04 February 2008).
31. Tiaden JD, Wenzel E, Berthold HK, Muller-Oerlinghausen B. Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system. Semin Thromb Hemost. 2005; 31: 371-380.
32. van der Hooft CS, Sturkenboom MC, van Grootheest K, Kingma HJ, Stricker BH. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf. 2006; 29: 161-168.
33. von Laue NC, Schwappach DL, Koeck CM. The epidemiology of preventable adverse drug events: a review of the literature. Wien Klin Wochenschr. 2003; 115: 407-415.
34. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008; 65: 573-579.
35. World Health Organization Collaborating Centre for International Drug Monitoring. Adverse Reaction Terminology. Uppsala 1984.
36. World Health Organization Collaborating Centre for Drug Statistical Methodology. Anatomical Therapeutic Chemical (ATC) Classification Index. Oslo 1992.
37. Zilleruelo I, Espinoza E, Ruiz I. Influence of the assessment of the severity on the frequency of adverse drug reactions (ADRs). Int J Clin Pharmacol Ther Toxicol. 1987; 25: 328-333.
38. Zopf Y, Rabe C, Neubert A, Gassman K, Rascher W, Hahn E, Brune K, Dormann H. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008; 64: 999-1004.
39. Zoppi M, Braunschweig S, Kuenzi UP, Maibach R, Hoigne R. Incidence of lethal adverse drug reactions in the comprehensive hospital drug monitoring, a 20-year survey, 1974-1993, based on the data of Berne/St. Gallen. Eur J Clin Pharmacol. 2000; 56: 427-430.